Cargando…

Phospholipase D inhibitors reduce human prostate cancer cell proliferation and colony formation

BACKGROUND: Phospholipases D1 and D2 (PLD1/2) hydrolyse cell membrane glycerophospholipids to generate phosphatidic acid, a signalling lipid, which regulates cell growth and cancer progression through effects on mTOR and PKB/Akt. PLD expression and/or activity is raised in breast, colorectal, gastri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noble, Amanda R, Maitland, Norman J, Berney, Daniel M, Rumsby, Martin G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785744/ https://www.ncbi.nlm.nih.gov/pubmed/29136407 http://dx.doi.org/10.1038/bjc.2017.391

Ejemplares similares

Phospholipase D2 in prostate cancer: protein expression changes with Gleason score
por: Noble, Amanda R., et al.
Publicado: (2019)

HDAC inhibitor confers radiosensitivity to prostate stem-like cells
por: Frame, F M, et al.
Publicado: (2013)

Drug-induced senescence bystander proliferation in prostate cancer cells in vitro and in vivo
por: Ewald, J A, et al.
Publicado: (2008)

γ-Tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways
por: Yap, W N, et al.
Publicado: (2008)

The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer
por: Diaz, R, et al.
Publicado: (2009)

Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer
por: Kozakai, N, et al.
Publicado: (2012)

Enhanced killing of androgen-independent prostate cancer cells using inositol hexakisphosphate in combination with proteasome inhibitors
por: Diallo, J-S, et al.
Publicado: (2008)

The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas
por: Seguin, F, et al.
Publicado: (2012)

D-Glucuronyl C5-epimerase suppresses small-cell lung cancer cell proliferation in vitro and tumour growth in vivo
por: Grigorieva, E V, et al.
Publicado: (2011)

Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel
por: Uzoh, C C, et al.
Publicado: (2011)

NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines
por: Yang, Y, et al.
Publicado: (2006)

Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels
por: Smalley, K S M, et al.
Publicado: (2007)

2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer
por: Tagg, S L C, et al.
Publicado: (2008)

Cancer cell proliferation is inhibited by specific modulation frequencies
por: Zimmerman, J W, et al.
Publicado: (2012)

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation
por: Seront, E, et al.
Publicado: (2013)

Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy
por: Yamamoto, Yoichiro, et al.
Publicado: (2016)

Inhibition of autophagy prevents cadmium-induced prostate carcinogenesis
por: Pal, Deeksha, et al.
Publicado: (2017)

Characterisations of human prostate stem cells reveal deficiency in class I UGT enzymes as a novel mechanism for castration-resistant prostate cancer
por: Williamson, S C, et al.
Publicado: (2013)

Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation
por: Cheng, G, et al.
Publicado: (2014)

Phellinus linteus sensitises apoptosis induced by doxorubicin in prostate cancer
por: Collins, L, et al.
Publicado: (2006)

Nuclear translocation of haeme oxygenase-1 is associated to prostate cancer
por: Sacca, P, et al.
Publicado: (2007)

Human fucosyltransferase 6 enables prostate cancer metastasis to bone
por: Li, J, et al.
Publicado: (2013)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer
por: Mittal, Karuna, et al.
Publicado: (2017)

Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice
por: Huynh, C K, et al.
Publicado: (2006)

Invasive characteristics of human prostatic epithelial cells: understanding the metastatic process
por: Hart, C A, et al.
Publicado: (2005)

Oxaliplatin-DNA adduct formation in white blood cells of cancer patients
por: Pieck, A C, et al.
Publicado: (2008)

Oxidative stress specifically downregulates survivin to promote breast tumour formation
por: Pervin, S, et al.
Publicado: (2013)

Phellinus linteus activates different pathways to induce apoptosis in prostate cancer cells
por: Zhu, T, et al.
Publicado: (2007)

Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells
por: Sinha, A K, et al.
Publicado: (2006)

The use of Raman spectroscopy to differentiate between different prostatic adenocarcinoma cell lines
por: Crow, P, et al.
Publicado: (2005)

Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress
por: Ketola, K, et al.
Publicado: (2012)

Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy
por: Koukourakis, M I, et al.
Publicado: (2014)

Loss of SLCO1B3 drives taxane resistance in prostate cancer
por: de Morrée, Ellen S, et al.
Publicado: (2016)

TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy
por: Pirovano, Giacomo, et al.
Publicado: (2017)

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors
por: Morgillo, F, et al.
Publicado: (2011)

Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026
por: Nutley, B P, et al.
Publicado: (2005)

BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation
por: Hennig, R, et al.
Publicado: (2008)

Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines
por: Uziel, O, et al.
Publicado: (2005)

Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer
por: White, N M A, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_dbk67em88avpk01f19k9k3b5qg